尽管一些安全隐患，FDA的疫苗专家组今天投票7:4建议批准辉瑞的RSV疫苗给60岁以上人群

Vaccine advisers to the FDA narrowly voted in favor of Pfizer’s RSV vaccine for adults over the age of 60, paving the way for approval of the first nation’s RSV vaccine, despite some safety concerns *****v9IBEQdEd0

— CNN (@CNN) March 1, 2023

https://cj.sina.com.cn/articles/view/2868676035/aafc85c3020014u02

60年研发黑洞，百亿RSV疫苗市场终于要起风了

https://m.jiemian.com/article/7602618.html

clinical-stage biopharmaceutical company focused on antiviral therapecutics for the respiratory syncytial virus(RSV), for 525 million dollars, last year。